NCT02652871 2019-11-15
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
M.D. Anderson Cancer Center
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company